Table of Contents

2024-9-1

Analytical Methods for Comparing Uncontrolled Trials with External Controls from Real-World Data: a Systematic Literature Review and Comparison to European Regulatory and Health Technology Assessment Practice

2024-9-1

Editorial Board

2024-9-1

Cost-of/Burden-of-Illness Studies: Steps Backward?

2024-8-1

Direct and Indirect Mapping of AQoL-6D onto EQ-5D-5L Utilities Using Data from a Multi-centre, Cross-Sectional Study of Malaysians with Chronic Heart Failure

2024-8-1

Cost-effectiveness analysis of bevacizumab biosimilars versus originator bevacizumab for metastatic colorectal cancer: a comparative study using real-world data

2024-8-1

Author Reply to “Cost-of/Burden-of-Illness Studies: Steps Backward?”

2024-8-1

Author Reply

2024-8-1

Table of Contents

2024-8-1

First-Line Treatment with Atezolizumab plus Bevacizumab and Chemotherapy for US Patients with Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis

2024-8-1

Editorial Board

2024-8-1

Assessing the health and welfare benefits of interventions using the Wider Societal Impacts framework

2024-8-1

Cost-Utility Analysis of Antipsychotic Reduction and Discontinuation in Patients with Long-term Schizophrenia and Psychosis in English Mental Health Trusts: The RADAR Study

2024-8-1

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

2024-8-1

Integrating Price Benchmarks and Comparative Clinical Effectiveness to Inform the Medicare Drug Price Negotiation Program

2024-8-1

The cost-effectiveness of seizure dogs for persons living with severe refractory epilepsy: results from the EPISODE study

2024-8-1

Age and Gender Differences in the Relationship Between Chronic Pain and Dementia Among Older Australians

2024-8-1

Does real option value influence oncologists’ treatment recommendations? A survey of U.S. oncologists

2024-8-1

Cost-effectiveness of HCC Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom

2024-8-1

The Impact of Additive PICOs in a European Joint Clinical Health Technology Assessment

2024-8-1

The cost-effectiveness of germline BRCA testing in metastatic prostate cancer followed by cascade testing of first-degree relatives of mutation carriers.

2024-7-1

Clinical Outcome Assessments Are Never “Validated”

2024-7-1

Methods for measuring and valuing informal care: A systematic review and meta-analysis in stroke

2024-7-1

Valuation of multi-dimensional health states with a “bolt-on”: is there a shortcut?

2024-7-1

An Exploratory Study of Alternative Timeframes and Descriptors for EQ-5D-5L in Obstructive Airway Diseases Using Mixed Methods.

2024-7-1

Traditional Methods Hold Their Ground Against Machine Learning in Predicting Potentially Inappropriate Medication Use in Older Adults

2024-7-1

EQ-5D-5L population scores in mainland China: results from a nationally representative survey 2021

2024-7-1

Understanding the Complex Interactions Between Interventions, Well-Being, and Resource Allocation

2024-7-1

Table of Contents

2024-7-1

PRIMCAT-CRC: a data-driven whole disease simulation model for predicting the number of colorectal cancer patients by stage and treatment line in Australia.

2024-7-1

Informing the US Medicare drug price negotiation for apixaban and rivaroxaban: Methodological considerations for value assessments many years after launch

2024-7-1

New IPECAD open-source model framework for the health technology assessment of early Alzheimer’s disease treatment: development and use cases

2024-7-1

Construct Validity, Reliability, and Responsiveness of the 10-Item Well-being Instrument for Use in Economic Evaluation Studies

2024-7-1

Cost-effectiveness of 2 Models of Pessary Care for Pelvic Organ Prolapse: Findings From the TOPSY Randomized Controlled Trial

2024-7-1

Mapping the Lequesne functional index into the EQ-5D-5L Utility index in patients with knee osteoarthritis

2024-7-1

Guiding Principles for Evaluating Vaccines in Joint Health Technology Assessment in the European Union: Preparing for the EU’s Regulation on HTA for Vaccines

2024-7-1

Discriminatory properties of QALY-based CEA for patients with disabilities: A Duchenne muscular dystrophy case study

2024-7-1

From Health to Wellbeing: Toward a Monetary Valuation of a Wellbeing-Adjusted Life-Year

2024-7-1

Evidence Quality and Health Technology Assessment Outcomes in Reappraisals of Drugs for Rare Diseases in Germany

2024-7-1

When are You Recovered? Defining Cutoff Points Using the Acute Respiratory Tract Infection Questionnaire

2024-7-1

Uncertainty in Long-Term Relative Effectiveness of Medicines in Health Technology Assessment

2024-7-1

A Tutorial on Value-Based Adaptive Designs: Could a Value-Based Sequential 2-Arm Design Have Created More Health Economic Value for the Big CACTUS Trial?

2024-7-1

Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case Study

2024-7-1

Editorial Board

2024-7-1

A new and improved experimental design for the discrete choice experiment module of the EQ-VT valuation protocol

2024-7-1

Examining the impact of structural uncertainty across ten type 2 diabetes models: Results from the 2022 Mount Hood Challenge

2024-7-1

The health benefits, costs, and cost-effectiveness of ultra-orphan drugs

2024-7-1

Choice Consistency in Discrete Choice Experiments: Does Numeracy Skill Matter? (VIH-2023-0494.R2).

2024-7-1

How many Monte Carlo samples are needed for probabilistic cost-effectiveness analyses?

2024-7-1

Linking reimbursement to patient benefits for advanced therapy medicinal products and other high-cost innovations: Policy recommendations for outcomes-based agreements in Europe

2024-7-1